CMS advises Bruker on the acquisition of PMOD Technologies LLC
Bruker has acquired PMOD Technologies LLC, a highly respected provider of research-use-only software for preclinical and molecular imaging, with a focus on molecular quantification and pharmacokinetic modeling. The PMOD software is widely used for the analysis of positron emission tomography (PET) studies in neurology, cardiology and oncology, both for preclinical and human molecular imaging research. Founded in 2003 as a University Hospital Zuerich spin-off, PMOD Technologies is based in Zuerich and has an innovative development team in Warsaw, Poland. The acquisition confirms Bruker's commitment to provide intuitive end-to-end solutions that make image analysis and quantitative knowledge extraction in nuclear molecular imaging research more productive and precise.
PMOD extends Bruker's portfolio of imaging software for clinical research and further enhances Bruker's expertise in nuclear molecular imaging. The portfolio now encompasses two leading-edge imaging research software packages used in magnetic resonance imaging (MRI) and nuclear molecular imaging (NMI) translational research: ParaVision® 360 and PMOD.
A team from CMS Switzerland and CMS Poland, led by partner Daniel Jenny, advised Bruker on all legal matters of the transaction.
CMS Switzerland
Dr Daniel Jenny (Lead Partner, Corporate/M&A)
Stefan Brunnschweiler (Relationship Partner)
Dr Felix Kesselring (Counsel, Life Sciences)
Dr Simone Brauchbar (Counsel, IP)
Dr Ferdinand Blezinger (Associate, Corporate/M&A)
Andrea Zindel (Associate, Corporate/M&A)
Sarah Keller (Associate, Employment)
Oliver Girstmair (Trainee, Corporate M&A)
CMS Poland
Katarzyna Dulewicz (Partner, Employment)
Maciej Andrzejewski (Senior Associate, Employment)
Michal Tutaj (Lawyer, Employment)
